Dutch umbrella federation of rare disease patient and parent organizations, providing patient representation across European health research consortia.
VSOP is the Dutch umbrella federation of patient and parent organizations, primarily representing families and individuals affected by rare, genetic, and congenital conditions. Their core work involves advocating for patients' rights in healthcare and research policy, facilitating meaningful patient involvement in clinical and scientific studies, and ensuring that the lived experience of patients and caregivers is embedded in research design, ethics, and outcomes. In H2020 consortia, they serve as the bridge between scientific teams and patient communities — contributing informed consent frameworks, stakeholder engagement, and dissemination to affected populations. They are not a research institution; their value is in making research more relevant, ethical, and patient-centered.
VSOP participated in both COSYN (psychiatric comorbidity) and PedCRIN (paediatric research infrastructure), consistently in the role of patient representative bridging scientific consortia with affected communities.
As a federation of rare disease parent and patient groups, VSOP's participation in COSYN — covering clinically overlapping psychiatric disorders — reflects their cross-condition advocacy capacity.
VSOP joined PedCRIN, the pan-European Paediatric Clinical Research Infrastructure Network, where parent organization input is essential for ethical and practical study design involving children.
PedCRIN (EUR 185,625 received) focused on building cross-border paediatric research capacity, placing VSOP in a system-level infrastructure role rather than a disease-specific one.
With only two projects entered in a narrow window (2016–2017) and no keyword data available, evolution is difficult to trace with confidence. The first project (COSYN) was disease-specific — focused on the biology and clinical overlap of psychiatric disorders — suggesting early engagement driven by condition-specific patient communities within the VSOP federation. The second project (PedCRIN) shifted toward research infrastructure at a European scale, covering all paediatric conditions rather than a single disease cluster, which points toward a broader institutional role. If this trend holds, VSOP may be positioning itself less as a condition-specific advocate and more as a structural partner in European clinical research governance.
VSOP appears to be moving from disease-specific patient representation toward broader cross-disease research infrastructure roles, making them increasingly relevant for large pan-European consortia that need credible, multi-condition patient engagement from the outset.
VSOP has never led a project — they join as participants, which is typical and appropriate for patient organizations whose value is expertise and community access, not project administration. Despite only two projects, they have accumulated 33 unique consortium partners across 18 countries, suggesting they are actively sought by large, multi-partner consortia who need recognized patient representation to meet ethical and regulatory expectations. Their relatively small EC funding share (EUR 117,812 average per project) is consistent with a non-technical partner role focused on engagement, dissemination, and stakeholder work rather than research execution.
Despite participating in only two projects, VSOP has connected with 33 unique consortium partners across 18 countries — a notably wide reach that reflects involvement in large, pan-European health consortia where patient organizations are brought in from across the continent. Their network is broadly European, with no visible geographic concentration beyond their Netherlands base.
VSOP is not a single-disease patient group — they are a federation, which means they can represent the patient perspective across multiple conditions simultaneously, making them unusually versatile for cross-disease or infrastructure projects. Unlike academic patient engagement consultants, VSOP has direct organizational relationships with the patient communities themselves, giving their involvement real legitimacy with ethics boards and regulators. For any consortium working in rare diseases, paediatric medicine, or psychiatric research that needs credible patient partnership rather than a token checkbox, VSOP brings institutional weight and a genuine network of affected families.
